As you continue with the treatment, the appetite-suppressing effects become more pronounced, making it easier to reduce food intake and stick to a healthier eating plan
When initial therapy proves insufficient, treatment escalation includes: Biologic DMARDs targeting specific inflammatory pathways (TNF inhibitors, IL-6 inhibitors, T-cell costimulation blockers, B-cell depleting agents) Targeted synthetic DMARDs such as JAK inhibitors (tofacitinib, baricitinib, upadacitinib), which carry FDA boxed warnings for serious cardiovascular events, malignancy, and thrombosis [24] [25] Combination DMARD therapy Short-term glucocorticoids for symptom control during treatment initiation Before starting biologic or targeted synthetic DMARDs, screening for tuberculosis and hepatitis B is recommended, along with appropriate vaccinations according to ACR guidelines
Not for direct human consumption.
As US patent exclusivity approaches its 2028 expiration, key dynamics to watch include potential label expansions (such as additional GVHD or inflammatory indications), intensifying competition from next-generation JAK inhibitors and Incytes ability to sustain patient demand while adapting to pricing reforms